Outcomes16

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

1 to 16 of 16

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Occurrence of Symptomatic Venous Thromboembolic Events	11 weeks	Treated population included patients who took at least one dose of Pradaxa. One additional patient was excluded from the analysis as they were missing their date of first dose.	participants	NUMBER
PRIMARY	Occurrence of Major Bleeding Events	11 weeks	Treated population included patients who took at least one dose of Pradaxa. One additional patient was excluded from the analysis as they were missing their date of first dose.	participants	NUMBER
SECONDARY	Dosage of Pradaxa at Initiation	Baseline	Treated population included patients who took at least one dose of Pradaxa. One additional patient was excluded from the analysis as they were missing their date of first dose.	participants	NUMBER
SECONDARY	Duration Between Surgery and First Dose of Pradaxa	11 weeks	Treated population included patients who took at least one dose of Pradaxa. One additional patient was excluded from the analysis as they were missing their date of first dose.	hours	MEAN
SECONDARY	Duration of Treatment	11 weeks	Treated population included patients who took at least one dose of Pradaxa. One additional patient was excluded from the analysis as they were missing their date of first dose.	days	MEAN
SECONDARY	Proportion of Patients With a Preoperative ALT Measurement	11 weeks	Treated population included patients who took at least one dose of Pradaxa. One additional patient was excluded from the analysis as they were missing their date of first dose.	percentage of participants	NUMBER
SECONDARY	Adherence to Treatment	11 weeks	Treated population included patients who took at least one dose of Pradaxa. One additional patient was excluded from the analysis as they were missing their date of first dose.	percent	MEAN
SECONDARY	Concomitant Treatments	11 weeks	Treated population included patients who took at least one dose of Pradaxa. One additional patient was excluded from the analysis as they were missing their date of first dose.	participants	NUMBER
SECONDARY	Number of Patients Who Switched to Another Anticoagulant Therapy	11 weeks		participants	NUMBER
SECONDARY	Prescription for the Surveillance of the Platelet Count on the Day of Hospital Discharge	11 weeks	Treated population included patients who took at least one dose of Pradaxa. One additional patient was excluded from the analysis as they were missing their date of first dose.	participants	NUMBER
SECONDARY	Prescription for Nursing Care and Nurse Visits on the Day of Hospital Discharge	11 weeks	Treated population included patients who took at least one dose of Pradaxa. One additional patient was excluded from the analysis as they were missing their date of first dose.	participants	NUMBER
SECONDARY	Reasons for Nurse Visits on the Day of Hospital Discharge	11 weeks	Treated population included patients who took at least one dose of Pradaxa. One additional patient was excluded from the analysis as they were missing their date of first dose.	participants	NUMBER
SECONDARY	Frequency of Nurse Visits on the Day of Hospital Discharge	11 weeks	Treated population included patients who took at least one dose of Pradaxa. One additional patient was excluded from the analysis as they were missing their date of first dose.	times per week	MEAN
SECONDARY	Duration of Unplanned Hospitalizations at Visit 3	11 weeks	Outcome measure was not analyzed.
SECONDARY	Reasons for Unplanned Hospitalizations at Visit 3	11 weeks	Outcome measure was not analyzed.
SECONDARY	Reasons for Usual Follow-up	11 weeks	Treated population included patients who took at least one dose of Pradaxa. One additional patient was excluded from the analysis as they were missing their date of first dose.	participants	NUMBER

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT01139658/outcomes

API reference For AI assistants